IP Verse

Antibodies With Modified Affinity To Fcrn That Promote Antigen Clearance - EP3181581

The patent EP3181581 was granted to Chugai Seiyaku Kabushiki Kaisha on Sep 25, 2024. The application was originally filed on Mar 30, 2011 under application number EP17154576A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3181581

CHUGAI SEIYAKU KABUSHIKI KAISHA
Application Number
EP17154576A
Filing Date
Mar 30, 2011
Status
Granted And Under Opposition
Aug 22, 2024
Grant Date
Sep 25, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANJun 25, 2025PLASSERAUDADMISSIBLE

Patent Citations (60) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0125023
DESCRIPTIONEP0239400
DESCRIPTIONEP2154157
DESCRIPTIONJP2008504970
DESCRIPTIONJPH0159878B
DESCRIPTIONUS2007141052
DESCRIPTIONWO0042072
DESCRIPTIONWO0061739
DESCRIPTIONWO02060919
DESCRIPTIONWO02079255
DESCRIPTIONWO0220565
DESCRIPTIONWO0231140
DESCRIPTIONWO0232925
DESCRIPTIONWO03002609
DESCRIPTIONWO2004044011
DESCRIPTIONWO2004058821
DESCRIPTIONWO2004106377
DESCRIPTIONWO2005037989
DESCRIPTIONWO2005040229
DESCRIPTIONWO2006020114
DESCRIPTIONWO2006031370
DESCRIPTIONWO2006053301
DESCRIPTIONWO2006067847
DESCRIPTIONWO2006067913
DESCRIPTIONWO2006073941
DESCRIPTIONWO2006105338
DESCRIPTIONWO2007041635
DESCRIPTIONWO2008045140
DESCRIPTIONWO2008092117
DESCRIPTIONWO2009086320
DESCRIPTIONWO2009113742
DESCRIPTIONWO2009125825
DESCRIPTIONWO2010033279
DESCRIPTIONWO9201047
DESCRIPTIONWO9203918
DESCRIPTIONWO9220791
DESCRIPTIONWO9306213
DESCRIPTIONWO9311236
DESCRIPTIONWO9312227
DESCRIPTIONWO9319172
DESCRIPTIONWO9402602
DESCRIPTIONWO9501438
DESCRIPTIONWO9501937
DESCRIPTIONWO9515388
DESCRIPTIONWO9515393
DESCRIPTIONWO9602576
DESCRIPTIONWO9633735
DESCRIPTIONWO9634096
DESCRIPTIONWO9813388
DESCRIPTIONWO9846777
DESCRIPTIONWO9954342
OPPOSITIONEP2275443
OPPOSITIONWO2009086320
OPPOSITIONWO2011111007
OPPOSITIONWO2016000813
SEARCHEP2275443
SEARCHUS2007148164
SEARCHWO0042072
SEARCHWO2009086320
SEARCHWO2009125825

Non-Patent Literature (NPL) Citations (96) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AMINO ACIDS, (1999), vol. 16, no. 3-4, pages 345 - 379-
DESCRIPTION- AMIT ET AL., SCIENCE, (1986), vol. 233, pages 747 - 753-
DESCRIPTION- ANGEW. CHEM. INT. ED., (2005), vol. 44, page 34-
DESCRIPTION- BIODRUGS, (2006), vol. 20, no. 3, pages 151 - 160-
DESCRIPTION- BR J CLIN PHARMACOL., (200705), vol. 63, no. 5, pages 548 - 561-
DESCRIPTION- CHEM SOC REV., (20040910), vol. 33, no. 7, pages 422 - 430-
DESCRIPTION- CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917-
DESCRIPTION- CHOTHIA ET AL., NATURE, (1989), vol. 342, page 877-
DESCRIPTION- CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628-
DESCRIPTION- CLIN PHARMACOL., (200804), vol. 48, no. 4, pages 406 - 417-
DESCRIPTION- COX KM ET AL., NAT. BIOTECHNOL., (200612), vol. 24, no. 12, pages 1591 - 1597-
DESCRIPTION- CURRENT OPINION IN BIOTECHNOLOGY, (2006), vol. 17, pages 653 - 658-
DESCRIPTION- CURRENT OPINION IN BIOTECHNOLOGY, (2007), vol. 18, pages 1 - 10-
DESCRIPTION- CURRENT OPINION IN STRUCTURAL BIOLOGY, (1997), vol. 7, pages 463 - 469-
DESCRIPTION- CURR OPIN BIOTECHNOL., (200912), vol. 20, no. 6, pages 685 - 691-
DESCRIPTION- CURR OPIN IMMUNOL, (200808), vol. 20, no. 4, pages 460 - 470-
DESCRIPTION- DRUG DISCOV TODAY, (200601), vol. 11, no. 1-2, pages 81 - 88-
DESCRIPTION- DRUG METAB DISPOS., (20070103), vol. 5, no. 1, pages 86 - 94-
DESCRIPTION- EBERT ET AL., BIO/TECHNOLOGY, (1994), vol. 12, pages 699 - 702-
DESCRIPTION- EMBO J., (19941215), vol. 13, no. 24, pages 5863 - 5870-
DESCRIPTION- EXPERT OPIN BIOL THER, (200705), vol. 7, no. 5, pages 763 - 779-
DESCRIPTION- FEBS LETTER, (1992), vol. 309, no. 1, pages 85 - 88-
DESCRIPTION- GHETIE V. ET AL, "Increasing the serum persistence of an IgG fragment by random mutagenesis", NAT BIOTECHNOL., (199707), vol. 15, no. 7, pages 637 - 640-
DESCRIPTION- G. KOHLER; C. MILSTEIN, METHODS ENZYMOL., (1981), vol. 73, pages 3 - 46-
DESCRIPTION- GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103-
DESCRIPTION- GRIFFITHS ET AL., EMBO J., (1994), vol. 13-
DESCRIPTION- HANSON CV ET AL, "Catalytic antibodies and their applications", CURR OPIN BIOTECHNOL, (200512), vol. 16, no. 6, pages 631 - 636-
DESCRIPTION- HINTON PR ET AL, "An engineered human IgGl antibody with longer serum half-life", J IMMUNOL., (20060101), vol. 176, no. 1, pages 346 - 356-
DESCRIPTION- INT IMMUNOL, (200112), vol. 13, no. 12, pages 1551 - 1559-
DESCRIPTION- INT IMMUNOL., (20061218), pages 1759 - 1769-
DESCRIPTION- JANICE M REICHERT ET AL, "Monoclonal antibody successes in the clinic", NATURE BIOTECHNOLOGY, (2005), vol. 23, pages 1073 - 1078-
DESCRIPTION- J BIOL CHEM., (20010302), vol. 276, no. 9, pages 6591 - 6604-
DESCRIPTION- J BIOL CHEM., (20060818), vol. 281, no. 33, pages 23514 - 23524-
DESCRIPTION- J BIOL CHEM., (20070119), vol. 282, no. 3, pages 1709 - 1717-
DESCRIPTION- J BIOL CHEM., (2007), vol. 282, no. 3, pages 1709 - 1717-
DESCRIPTION- J EXP MED., (19941201), vol. 180, no. 6, pages 2377 - 2381-
DESCRIPTION- J. EXP. MED., (1995), vol. 108-
DESCRIPTION- J. IMMUNOL., (1994), vol. 152, pages 4958 - 4968-
DESCRIPTION- J IMMUNOL., (2002), vol. 169, no. 9, pages 5171 - 5180-
DESCRIPTION- J IMMUNOL., (2009), vol. 182, no. 12, pages 7663 - 7671-
DESCRIPTION- J IMMUNOL METHODS, (200406), vol. 289, no. 1-2, pages 65 - 80-
DESCRIPTION- J IMMUNOL METHODS, (20061020), vol. 316, no. 1-2, pages 133 - 143-
DESCRIPTION- J. MOL. BIOL., (2003), vol. 324, pages 645 - 657-
DESCRIPTION- JOURNAL OF IMMUNOLOGY, (2009), vol. 182, pages 7663 - 7671-
DESCRIPTION- KIM SJ ET AL, "Antibody engineering for the development of therapeutic antibodies.", MOL CELLS., (20050831), vol. 20, no. 1, pages 17 - 29-
DESCRIPTION- K. SATO ET AL., CANCER RES., (1993), vol. 53, pages 10.01 - 10.06-
DESCRIPTION- KUNKEL, PROC. NATL. ACAD. SCI. USA, (1910), vol. 82, page 488-
DESCRIPTION- MA ET AL., EUR. J. IMMUNOL., (1994), vol. 24, pages 131 - 138-
DESCRIPTION- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597-
DESCRIPTION- MENDEZ ET AL., NAT. GENET., (1997), vol. 15, pages 146 - 156-
DESCRIPTION- METHODS MOL BIOL., (2002), vol. 178, pages 87 - 100-
DESCRIPTION- METHODS MOL BIOL, (2010), vol. 602, pages 93 - 104-
DESCRIPTION- METHODS MOL BIOL., (2010), vol. 602, pages 93 - 104-
DESCRIPTION- MOL CELL BIOL., (1988), vol. 8, pages 466 - 472-
DESCRIPTION- MOLECULAR CELL, (200104), vol. 7, pages 867 - 877-
DESCRIPTION- NAT BIOTECHNOL., (19970715), pages 637 - 640-
DESCRIPTION- NAT BIOTECHNOL., (200509), vol. 23, no. 9, pages 1126 - 1136-
DESCRIPTION- NAT BIOTECHNOL., (20051023), pages 1283 - 1288-
DESCRIPTION- NAT MED, (200301), vol. 9, no. 1, pages 47 - 52-
DESCRIPTION- NAT MED., (200301), vol. 9, no. 1, pages 47 - 52-
DESCRIPTION- PAVLOU AK ET AL, "The therapeutic antibodies market to 2008", EUR J PHARM BIOPHARM., (200504), vol. 59, no. 3, pages 389 - 396-
DESCRIPTION- PHARMACOKINET PHARMACODYN., (200112), vol. 28, no. 6, pages 507 - 532-
DESCRIPTION- PHARM RES, (200601), vol. 23, no. 1, pages 95 - 103-
DESCRIPTION- PROC NATL ACAD SCI USA., (19960723), vol. 93, no. 15, pages 7843 - 7848-
DESCRIPTION- PROC. NATL. ACAD. SCI. U.S.A., (2002), vol. 99, no. 26, pages 16899 - 16903-
DESCRIPTION- PROC NATL ACAD SCI USA., (20060314), vol. 103, no. 11, pages 4005 - 4010-
DESCRIPTION- PROC NATL ACAD SCI USA., (20061205), vol. 103, no. 49, pages 18709 - 18714-
DESCRIPTION- PROTEIN ENG DES SEL, (201004), vol. 23, no. 4, pages 195 - 202-
DESCRIPTION- PROTEIN SCIENCE, (1995), vol. 4, pages 2411 - 2423-
DESCRIPTION- PROTEIN SCIENCE, (2006), vol. 15, pages 14 - 27-
DESCRIPTION- RAJPAL A. ET AL, "A general method for greatly improving the affinity of antibodies by using combinatorial libraries", PROC NATL ACAD SCI USA., (20050606), vol. 102, no. 24, pages 8466 - 8471-
DESCRIPTION- RATHANASWAMI P. ET AL, "Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8", BIOCHEM BIOPHYS RES COMMUN., (20050909), vol. 334, no. 4, pages 1004 - 1013-
DESCRIPTION- SATO ET AL., CANCER RES., (1993), vol. 53-
DESCRIPTION- THE JOURNAL OF IMMUNOLOGY, (2009), vol. 182, pages 7663 - 7671-
DESCRIPTION- VALLE ET AL., NATURE, (1981), vol. 291, pages 338 - 340-
DESCRIPTION- VAUGHAN ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 309 - 314-
DESCRIPTION- WATERHOUSES ET AL., NUCLEIC ACIDS RES., (1993), vol. 21, pages 2265 - 2266-
DESCRIPTION- WU H. ET AL, "Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract", J MOL BIOL., (2007), vol. 368, pages 652 - 665-
EXAMINATION- RUDIKOFF S ET AL, "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, (19820301), vol. 79, doi:10.1073/PNAS.79.6.1979, ISSN 0027-8424, pages 1979 - 1983, XP007901436
OPPOSITION- D10 - Experimental report on Xolair® (filed as D2 in the parent case ‘955 on 2 February 2018)-
OPPOSITION- D4 - BoA preliminary opinion on patent granted from A3 dated 21 June 2022-
OPPOSITION- D5 - BoA decision of revocation of patent granted from A3 dated 27 October 2022-
OPPOSITION- D6 - Annex A filed by Patent Proprietor in parent case ‘955 appeal proceedings dated 28 April 2020-
OPPOSITION- Carlos Vaccaro, Jinchun Zhou, Raimund J Ober, E Sally Ward, "Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels", Nature Biotechnology, Gale Group Inc., (20051001), vol. 23, no. 10, doi:10.1038/nbt1143, ISSN 10870156, pages 1283 - 1288, XP055049342
OPPOSITION- Jonathan Zalevsky, Aaron K Chamberlain, Holly M Horton, Sher Karki, Irene W L Leung, Thomas J Sproule, Greg A Lazar, Derry C Roopenian, John R Desjarlais, "Enhanced antibody half-life improves in vivo activity", Nature Biotechnology, Gale Group Inc., (20100201), vol. 28, no. 2, doi:10.1038/nbt.1601, ISSN 10870156, pages 157 - 159, XP055049187
OPPOSITION- Igawa T; Ishii S; Tachibana T; Maeda A; Higuchi Y; Shimaoka S; Moriyama C; Watanabe T; Takubo R; Doi Y; Wakabayashi T; Hayasaka A; Kadono S; Miyazaki T; Haraya K; Sekimori Y; Kojima T; Nabuchi Y; Aso Y; Kawabe Y; Hattori K, "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20101101), vol. 28, no. 11, doi:10.1038/nbt.1691, ISSN 1087-0156, pages 1203 - 1207, XP009153598
OPPOSITION- Derry C. Roopenian & Shreeram Akilesh, "FcRn: the neonatal Fc receptor comes of age.", Nature Reviews. Immunology, Nature Publishing Group, United Kingdom, United Kingdom , (20070901), vol. 7, no. 9, doi:10.1038/nri2155, ISSN 1474-1741, pages 715 - 725, XP002753502
OPPOSITION- SHIELDS R L,ET AL, "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20010302), vol. 276, no. 9, doi:10.1074/jbc.M009483200, ISSN 0021-9258, pages 6591 - 6604, XP002271092
OPPOSITION- DALL'ACQUA W F ET AL, "Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20060621), vol. 281, no. 33, doi:10.1074/jbc.M604292200, ISSN 0021-9258, pages 23514 - 23524, XP002404904
OPPOSITION- Tomoyuki Igawa, Kenta Haraya, Kunihiro Hattori, "Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation", Immunological Reviews, Wiley-Blackwell Publishing, Inc., US, US , (20160301), vol. 270, no. 1, doi:10.1111/imr.12392, ISSN 0105-2896, pages 132 - 151, XP055585172
OPPOSITION- Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Tatsuhiko Tachibana, Yuki Iwayanagi, Futa Mimoto, Yoshinobu Higuchi, Shinya Ishii, Shigero Tamba, Naoka Hironiwa, Kozue Nagano, Tetsuya Wakabayashi, Hiroyuki Tsunoda, Kunihiro Hattori, "Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo", PLoS ONE, vol. 8, no. 5, doi:10.1371/journal.pone.0063236, page e63236, XP055172504
OPPOSITION- YEUNG YIK ANDY, ET AL, "Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates", The Journal of Immunology, (20090601), vol. 182, no. 12, doi:10.4049/JIMMUNOL.0804182, ISSN 0022-1767, pages 7663 - 7671, XP002566420
SEARCH- DALL'ACQUA W F ET AL, "Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20021101), vol. 169, no. 9, ISSN 0022-1767, pages 5171 - 5180, XP002384463 [YD] 1-10 * page 5175; table 1 *-
SEARCH- SHIELDS R L ET AL, "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC., BALTIMORE, MD, US, (20010302), vol. 276, no. 9, doi:10.1074/JBC.M009483200, ISSN 0021-9258, pages 6591 - 6604, XP002271092 [Y] 1-10 * page 6592, column 2 - page 6593, column 1; table 1 *
SEARCH- GESTUR VIDARSSON ET AL, "IgG Subclasses and Allotypes: From Structure to Effector Functions", FRONTIERS IN IMMUNOLOGY, (20141020), vol. 5, doi:10.3389/fimmu.2014.00520, XP055166978 [T] 1-10 * figure 3 *
SEARCH- YEUNG YIK ANDY ET AL, "Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20090601), vol. 182, no. 12, doi:10.4049/JIMMUNOL.0804182, ISSN 0022-1767, pages 7663 - 7671, XP002566420 [Y] 1-10 * figure 5 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents